Deconstructing cancer with precision genome editing

2024/04/17 by Grace A. Johnson, Samuel I. Gould, Francisco J. Sánchez‐Rivera · 1 voice
Biochemistry, Genetics and Molecular Biology · #CRISPR and Genetic Engineering #Virus-based gene therapy research #RNA and protein synthesis mechanisms

paper · pdf · doi:10.1042/bst20230984

openalex publication_date 2024/04/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

Recent advances in genome editing technologies are allowing investigators to engineer and study cancer-associated mutations in their endogenous genetic contexts with high precision and efficiency. Of these, base editing and prime editing are quickly becoming gold-standards in the field due to their versatility and scalability. Here, we review the merits and limitations of these precision genome editing technologies, their application to modern cancer research, and speculate how these could be integrated to address future directions in the field.

Citations

• Mechanisms and Consequences of Double‐Strand DNA Break Formation in Chromatin
• A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
• ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
• Functions and Regulation of RNA Editing by ADAR Deaminases
• Hallmarks of Cancer: The Next Generation
• Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
• U1 snRNP regulates cancer cell migration and invasion in vitro
• Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
• Anomalous collapses of Nares Strait ice arches leads to enhanced export of Arctic sea ice
• Engineered pegRNAs improve prime editing efficiency
• Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution

Discussions

• Base editing and prime editing are quickly becoming gold-standards of genome editing technologies, but what are their merits, limitations, and applications to cancer research? @‌fjsanchezrivera, Grac [bsky, 0 points, 0 comments]